This gene encodes two proteins, the SART1(800) protein expressed in the nucleus of the majority of proliferating cells, and the SART1(259) protein expressed in the cytosol of epithelial cancers. The SART1(259) protein is translated by the mechanism of -1 frameshifting during posttranscriptional regulation; its full-length sequence is not published yet. The two encoded proteins are thought to be involved in the regulation of proliferation. Both proteins have tumor-rejection antigens. The SART1(259) protein possesses tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes in cancer patients. This SART1(259) antigen may be useful in specific immunotherapy for cancer patients and may serve as a paradigmatic tool for the diagnosis and treatment of patients with atopy. The SART1(259) protein is found to be essential for the recruitment of the tri-snRNP to the pre-spliceosome in the spliceosome assembly pathway.
Dilutions
WB 1:500 - 1:2000 IP 1:20 - 1:50
Format
Calculated MW
90kDa
Observed MW
120kDa
Immunogen
Recombinant fusion protein containing a sequence corresponding to amino acids 1-255 of human SART1 (NP_005137.1).
Modification
Unmodified
Storage
-20°C
Images
Western blot analysis of extracts of various cell lines, using SART1 antibody (144-08569) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 10s.
Immunoprecipitation analysis of 150ug extracts of Jurkat cells using 3ug SART1 antibody (144-08569). Western blot was performed from the immunoprecipitate using SART1 antibody (144-08569) at a dilition of 1:1000.
Expiration:
12 months from the date of shipment when stored properly.
